The protective effect of melatonin against brain oxidative stress and hyperlocomotion in a rat model of mania induced by ouabain

Behavioural Brain Research

Volumn 271, Issue , 2014, Pages 316-324

  Souza, Leandro C ^a   Wilhelm, Ethel Antunes ^b   Bortolatto, Cristiani Folharini ^b   Nogueira, Cristina Wayne ^b   Boeira, Silvana P ^a   Jesse, Cristiano R ^a  

^a UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Bipolar disorder; Melatonin; Ouabain; Oxidative stress

Indexed keywords

CARBONYL DERIVATIVE; CATALASE; GLUTATHIONE PEROXIDASE; LITHIUM CHLORIDE; MELATONIN; OUABAIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOL DERIVATIVE; NEUROPROTECTIVE AGENT; TRANQUILIZER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; DRUG EFFICACY; ENZYME ACTIVITY; EXPERIMENTAL HYPERACTIVITY; HIPPOCAMPUS; MALE; MANIA; NEUROPROTECTION; NONHUMAN; OPEN FIELD BEHAVIOR; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RAT MODEL; ANIMAL; BIPOLAR DISORDER; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; LOCOMOTION; METABOLISM; MOTOR ACTIVITY; PROTEIN CARBONYLATION; PSYCHOLOGY; WISTAR RAT;

ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CATALASE; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; GLUTATHIONE PEROXIDASE; HIPPOCAMPUS; LITHIUM CHLORIDE; LOCOMOTION; MALE; MELATONIN; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OUABAIN; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

EID: 84903787861     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.06.030     Document Type: Article

References (55)

1. Leboyer M., Kupfer D.J. Bipolar disorder: new perspectives in health care and prevention. J Clin Psychiatry 2010, 71:1689-1695.
2. Kupfer D.J. The increasing medical burden in bipolar disorder. JAMA 2005, 293:2528-2530.
3. Torpy J.M., Lynm C., Glass R.M. Bipolar disorder. JAMA 2009, 301:564.
4. El-Mallakh R.S., Wyatt R.J. The Na,K-ATPase hypothesis for bipolar illness. Biol Psychiatry 1995, 37:235-244.
5. Herman L., Hougland T., El-Mallakh R.S. Mimicking human bipolar ion dysregulation models mania in rats. Neurosci Biobehav Rev 2007, 31:874-881.
6. Brocardo P.S., Budni J., Pavesi E., Franco J.L., Uliano-Silva M., Trevisan R., Terenzi M.G., Dafre A.L., Rodrigues A.L. Folic acid administration prevents ouabain-induced hyperlocomotion and alterations in oxidative stress markers in the rat brain. Bipolar Disord 2010, 12:414-424.
7. El-Mallakh R.S., El-Masri M.A., Huff M.O., Li X.P., Decker S., Levy R.S. Intracerebroventricular administration of ouabain as a model of mania in rats. Bipolar Disord 2003, 5:362-365.
8. Price L.H., Heninger G.R. Lithium in the treatment of mood disorders. N Engl J Med 1994, 331:591-598.
9. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan E., Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002, 20:171-175.
10. Machado-Vieira R., Andreazza A.C., Viale C.I., Zanatto V., Cereser V., Vargas J.R., Kapczinski R., Portela F., Souza L.V., Salvador D.O., Gentil V.M. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007, 421:33-36.
11. Ozcan M.E., Gulec M., Ozerol E., Polat R., Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004, 19:89-95.
12. Brüning C.A., Prigol M., Luchese C., Pinton S., Nogueira C.W. Diphenyl diselenide ameliorates behavioral and oxidative parameters in an animal model of mania induced by ouabain. Prog Neuropsychopharmacol Biol Psychiatry 2012, 38:168-174.
13. Frey B.N., Valvassori S.S., Réus G.Z., Martins M.R., Petronilho F.C., Bardini K., Dal-Pizzol F., Kapczinski F., Quevedo J. Effects of lithium and valproate on amphetamine induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006, 31:326-332.
14. Jornada L.K., Valvassori S.S., Steckert A.V., Moretti M., Mina F., Ferreira C.L., Arent C.O., Dal-Pizzol F., Quevedo J. Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. J Psychiatr Res 2011, 45:162-168.
15. Etain B., Dumaine A., Bellivier F., Pagan C., Francelle L., Goubran-Botros H., Moreno S., Deshommes J., Moustafa K., Le Dudal K., Mathieu F., Henry C., Kahn J.P., Launay J.M., Mühleisen T.W., Cichon S., Bourgeron T., Leboyer M., Jamain S. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet 2012, 2118:4030-4037.
16. Salvatore P., Ghidini S., Zita G., De Panfilis C., Lambertino S., Maggini C., Baldessarini R.J. Circadian activity rhythm abnormalities in ill and recovered bipolar I disorder patients. Bipolar Disord 2008, 10:256-265.
17. Pacchierotti C., Iapichino S., Bossini L., Pieraccini F., Castrogiovanni P. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol 2001, 22:18-32.
18. Bonnefont-Rousselot D., Collin F. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology 2010, 278:55-67.
19. Sugden D. Psychopharmacological effects of melatonin in mouse and rat. J Pharmacol Exp Ther 1983, 227:587-591.
20. Papp M., Litwa E., Gruca P., Mocaër E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol 2006, 17:9-18.
21. Tuzcua M., Baydas G. Effect of melatonin and vitamin E on diabetes-induced learning and memory impairment in rats. Eur J Pharmacol 2006, 537:106-110.
22. Ersahin M., Toklu H.Z., Cetinel S., Yüksel M., Yeǧen B.C., Sener G. Melatonin reduces experimental subarachnoid hemorrhage-induced oxidative brain damage and neurological symptoms. J Pineal Res 2009, 46:324-332.
23. Tchekalarova J., Petkova Z., Pechlivanova D., Moyanova S., Kortenska L., Mitreva R., Lozanov V., Atanasova D., Lazarov N., Stoynev A. Prophylactic treatment with melatonin after status epilepticus: effects on epileptogenesis, neuronal damage, and behavioral changes in a kainate model of temporal lobe epilepsy. Epilepsy Behav 2013, 27:174-187.
24. Patki G., Lau Y.S. Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease. Pharmacol Biochem Behav 2011, 994:704-711.
25. Wilhelm E.A., Jesse C.R., Bortolatto C.F., Nogueira C.W. Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington's disease: protective effect of melatonin. Eur J Pharmacol 2013, 701:65-72.
26. Baño Otalora B., Popovic N., Gambini J., Popovic M., Viña J., Bonet-Costa V., Reiter R.J., Camello P.J., Rol M.Á., Madrid J.A. Circadian system functionality, hippocampal oxidative stress, and spatial memory in the APPswe/PS1dE9 transgenic model of Alzheimer disease: effects of melatonin or ramelteon. Chronobiol Int 2012, 29:822-834.
27. El-Mallakh R.S., Harrison L.T., Li R., Changaris D.G., Levy R.S. An animal model for mania: preliminary results. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19:955-962.
28. Agrawal R., Tyagi E., Shukla R., Nath C. A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia. Neuropharmacology 2009, 56:779-787.
29. Machado-Vieira R., Schmidt A.P., Avila T.T., Kapczinski F., Soares J.C., Souza D.O., Portela L.V. Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain. Life Sci 2004, 76:805-811.
30. Loetchutinat C., Kothan S., Dechsupa S., Meesungnoen J., Jay-Gerin J., Mankhetkorn S. Spectrofluorometric determination of intracellular levels of reactive oxygen species in drug-sensitive and drug-resistant cancer cells using the 2',7'-dichlorofluorescein diacetate assay. Radiat Phys Chem 2005, 72:323-331.
31. Yan L.J., Traber M.G., Packer L. Spectrophotometric method for determination of carbonyls in oxidatively modified apolipoprotein B of human low-density lipoproteins. Anal Biochem 1995, 228:349-351.
32. Levine L.R., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., Ahn B.W., Shaltiel S., Stadtman E. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990, 186:464-478.
33. Ellman G.L., Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
34. Misra H.P., Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and simple assay for superoxide dismutase. J Biol Chem 1972, 247:3170-3175.
35. Aebi H. Catalase in vitro. Methods Enzymol 1984, 105:121-126.
36. Wendel A. Glutathione peroxidase. Methods Enzymol 1981, 77:325-333.
37. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem 1976, 72:248-254.
38. Young A.H., Newham J.I. Lithium in maintenance therapy for bipolar disorder. J Psychopharmacol 2006, 20:17-22.
39. Riegel R.E., Valvassori S.S., Elias G., Réus G.Z., Steckert A.V., de Souza B., Petronilho F., Gavioli E.C., Dal-Pizzol F., Quevedo J. Animal model of mania induced by ouabain: evidence of oxidative stress in submitochondrial particles of the rat brain. Neurochem Int 2009, 55:491-495.
40. Ter-Minassian A., Cerebral metabolism, brain injury. Ann Fr Anesth Reanim 2006, 7:714-721.
41. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:463-493.
42. Frey B.N., Andreazza A.C., Kunz M., et al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:283-285.
43. Riegel R.E., Valvassori S.S., Moretti M., Ferreira C.L., Steckert A.V., Souza B., Dal-Pizzol F., Quevedo J. Intracerebroventricular ouabain administration induces oxidative stress in the rat brain. Int J Dev Neurosci 2010, 28:233-237.
44. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000, 62:649-671.
45. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011, 14:123-130.
46. Dean O.M., van den Buuse M., Bush A.I., Copolov D.L., Ng F., Dodd S., Berk M. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem 2009, 16:2965-2976.
47. Magalhães P.V., Dean O.M., Bush A.I., Copolov D.L., Malhi G.S., Kohlmann K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Berk M. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 2011, 33:374-378.
48. Berk M., Dean O., Cotton S.M., Gama C.S., et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 2011, 135:389-894.
49. Lucheses C., Stangherlin E.C., Gay B.M., Nogueira C.W. Antioxidant effect of diphenyl diselenide on oxidative damage. Ecotoxicol Environ Saf 2008, 72:248-254.
50. Halliwell B., Gutteridge J.M.C. Free radicals in biology and medicine 1999, Oxford University Press, New York, NY.
51. Savas H.A., Gergerlioglu H.S., Armutcu F., et al. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry 2006, 7:51-55.
52. Gonzales E., Julien B., Serrière-Lanneau V., Nicou A., Doignon I., Lagoudakis L., Garcin I., Azoulay D., Duclos-Vallée J.C., Castaing D., Samuel D., Hernandez-Garcia A., Awad S.S., Combettes L., Thevananther S., Tordjmann T. ATP release after partial hepatectomy regulates liver regeneration in the rat. J Hepatol 2010, 52:54-62.
53. Maldonado M.D., Pérez-San-Gregorio M.A., Reiter R.J. The role of melatonin in the immuno-neuro-psychology of mental disorders. Recent Pat CNS Drug Discovery 2009, 4:61-69.
54. Dodd S., Maes M., Anderson G., Dean O.M., Moylan S., Berk M. Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:135-145.
55. Osseni R.A., Rat P., Bogdan A., Warnet J.M., Touitou Y. Evidence of prooxidant and antioxidant action of melatonin on human liver cell line HepG2. Life Sci 2000, 68:387-399.